JAMES J BURNS
Broker in Watertown, MA
License number
Massachusetts 9069954
Issued Date
Sep 28, 2004
Expiration Date
Nov 24, 2010
Type
Salesperson
Address
Address
Watertown, MA 02472
Professional information
Controlled Release Of Anti-Arrhythmic Agents
US Patent:
7022343, Apr 4, 2006
Filed:
Dec 27, 2001
Appl. No.:
10/033274
Inventors:
C. Michael Philbrook - Boston MA, US
James W. Burns - Watertown MA, US
Kevin C. Skinner - Andover MA, US
Robert J. Miller - Quincy MA, US
James W. Burns - Watertown MA, US
Kevin C. Skinner - Andover MA, US
Robert J. Miller - Quincy MA, US
Assignee:
Genzyme Corporation - Cambridge MA
International Classification:
A61K 9/00, A61K 9/14
US Classification:
424484, 424400, 424422, 424425, 424488
Abstract:
Methods for the simple, reliable application and local controlled release of selected anti-arrhythmia drugs from a hydrogel applied to or polymerized on the tissues of the heart or its vessels, especially in conjunction with cardiac bypass or other cardiac surgery, have been developed. The anti-arrhythmia drugs are incorporated into hydrogels that biodegrade and adhere to the tissues to which the anti-arrhythmic drugs are to be delivered. The hydrogels may be formed in vitro or in vivo. In a preferred embodiment, the drugs are effective to lengthen atrial effective refractory period. A particularly preferred drug is amiodarone.
Prevention Of Adhesions
US Patent:
6841153, Jan 11, 2005
Filed:
Oct 1, 1999
Appl. No.:
09/787144
Inventors:
Nasser Chegini - Gainesville FL, US
James Burns - Watertown MA, US
Michael P. Diamond - Grosse Pointe MI, US
Lena E. Holmdahl - Cambridge MA, US
James Burns - Watertown MA, US
Michael P. Diamond - Grosse Pointe MI, US
Lena E. Holmdahl - Cambridge MA, US
Assignee:
University of Florida - Gainesville FL
Wayne State University - Detroit MI
Genzyme Corporation - Framingham MA
Wayne State University - Detroit MI
Genzyme Corporation - Framingham MA
International Classification:
A61K 39395, A61K 3944, C07K 1628
US Classification:
4241451, 4241781, 53038824, 5303892, 5303911
Abstract:
Methods for the prevention of adhesion formation involve the administration of therapeutic formulations to a patient which include antibodies to TIMP-1 or TIMP-1 antisense oligonucleotides. The formulations can also include suitable carriers, such as a hyaluronic acid matrix, for optimal administration. The treatment procedure can be initiated and monitored by a diagnostic procedure which involves the detection of elevated levels of TIMP-1 in a patient.
Prevention Of Adhesions
US Patent:
2005015, Jul 14, 2005
Filed:
Dec 2, 2004
Appl. No.:
11/002036
Inventors:
Nasser Chegini - Gainesville FL, US
James Burns - Watertown MA, US
Michael Diamond - Grosse Pointe Shores MI, US
Lena Holmdahl - Cambridge MA, US
James Burns - Watertown MA, US
Michael Diamond - Grosse Pointe Shores MI, US
Lena Holmdahl - Cambridge MA, US
International Classification:
A61K048/00, A61K039/395, C07K016/28, A61K031/728
US Classification:
424143100, 514044000, 530388220, 514054000
Abstract:
Methods for the prevention of adhesion formation involve the administration of therapeutic formulations to a patient which include antibodies to TIMP-1 or TIMP-1 antisense oligonucleotides. The formulations can also include suitable carriers, such as a hyaluronic acid matrix, for optimal administration. The treatment procedure can be initiated and monitored by a diagnostic procedure which involves the detection of elevated levels of TIMP-1 in a patient.